Project Grant HT94252310501

This Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $400,000 to Senex Biotechnology Inc. to develop a nanoparticle formulation of a mediator kinase inhibitor drug candidate, SNX631-6, for the treatment of peritoneal ovarian cancer metastases. The goal is to optimize the nanoparticle formulation for improved pharmacokinetics and efficacy compared to oral administration when delivered intraperitoneally. The project will assess the...

The National Cancer Institute (NCI) has awarded Nuago Therapeutics Inc. a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395). The funding will support the development of a novel, short RNA therapeutic to treat ovarian cancer. This research aims to address the limitations of existing targeted cancer therapies and checkpoint inhibitor immunotherapies, which have had limited success in curing solid cancers. The project will run from June 9, 2025 to May...

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...

This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of engineered extracellular vesicle (EV) therapy for the treatment of glioblastoma (GBM), a highly aggressive form of brain cancer. Round Table Research, Inc., in collaboration with researchers at the University of North Carolina-Chapel Hill, has developed a novel EV drug carrier derived from induced neural stem cells (iNSCs) that demonstrates significant anti-tumor...

The National Cancer Institute awarded a $276,544 Project Grant to Ioncologi Inc. under the Cancer Treatment Research federal grant program (CFDA 93.395) to develop IOI7, a therapy utilizing autologous, ex vivo-expanded, immunomodulatory hematopoietic stem cells (HSC), for the treatment of immune checkpoint inhibitor (ICI)-resistant glioblastoma. The key objectives of this project are to: (1) optimize HSC expansion using a closed, scalable, and commercially viable production platform; (2)...

This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...

This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Beken Bio, Inc. aims to develop a highly sensitive, minimally invasive laboratory test to detect early-stage ovarian cancer by assaying relevant biomarkers on circulating extracellular vesicles in patient plasma. The project will utilize a novel technology to identify key proteins in extracellular vesicles from various ovarian cancer subtypes and employ a machine...

This $816,676 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports a study by the Fred Hutchinson Cancer Center (doing business as Seattle Cancer Care Alliance) to conduct a multiomic evaluation of ovarian cancer responses to heated intraperitoneal chemotherapy (HIPEC). The 3-year study, with a period of performance from September 30, 2024 to August 31, 2027, aims to advance understanding of how HIPEC...

The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $452,540 Project Grant to the Sloan-Kettering Institute for Cancer Research to develop a novel T-cell imaging paradigm that will provide real-time information on the endogenous T-cell trafficking, tumor targeting, and persistence in patients with multiple myeloma (MM) undergoing bispecific T-cell engager antibody (BiTEA) treatment. The goal is to better understand T-cell engagement and trafficking...